Two bi-specific protein constructs have been designed that direct the body's T cells to kill HIV-infected cells. The feat provides a step on the path to removing the latent virus reservoir that persists in patients on antiretroviral therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Notes
References
Sung, J. A. M. et al. J. Clin. Invest. 125, 4077–4090 (2015).
Pegu, A. et al. Nature Commun. 6, 8447 (2015).
Archin, N. M. et al. Nature 487, 482–485 (2012).
Elliott, J. H. et al. PLoS Pathog. 10, e1004473 (2014).
Rasmussen, T. A. et al. Lancet HIV 1, e13–e21 (2014).
Deng, K. et al. Nature 517, 381–385 (2015).
Berg, J. et al. Proc. Natl Acad. Sci. USA 88, 4723–4727 (1991).
Traunecker, A., Lanzavecchia, A. & Karjalainen, K. EMBO J. 10, 3655–3659 (1991).
Bargou, R. et al. Science 321, 974–977 (2008).
Richman, D. D. et al. Science 323, 1304–1307 (2009).
Author information
Authors and Affiliations
Corresponding author
Related links
Related links
Related links in Nature Research
Rights and permissions
About this article
Cite this article
Richman, D. Cure by killing. Nature 528, 198–199 (2015). https://doi.org/10.1038/nature16321
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature16321